Please wait a minute...
Clinical and Experimental Obstetrics & Gynecology  2017, Vol. 44 Issue (2): 203-207    DOI: 10.12891/ceog3262.2017
Original Research Previous articles | Next articles
Analysis of bromocriptine treatment in pregnant pituitary prolactinoma patients
W. Lian1, *(), N. Liu2, R.Z. Wang1, B. Xing1, Y. Yao1
1 Department of Neurosurgery, Peking Union Medical College Hospital, Beijing Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China
2 Department of Neurosurgery, The Second Affiliated Hospital, Shandong University of Traditional Chinese Medicine, Jinan, China
Download:  PDF
Export:  BibTeX | EndNote (RIS)      
Abstract  
Objective: To investigate the therapeutic effects and duration of bromocriptine treatment during pregnancy in patients with pituitary prolactinoma. Materials and Methods: A retrospective analysis of the clinical data of 230 female pituitary prolactinoma patients at the Beijing Union Medical College Hospital neurosurgery clinic from January 2001 to May 2014 was conducted. When confirmed pregnant, patients in the control group immediately stopped taking bromocriptine, but patients in the treatment group continued to take the same dose of bromocriptine. Results: The embryos stop rate in the control group was 16.7%, significantly higher than the rate in the natural population (p < 0.05), while the rate in the treatment group (0.9%) not statistically different from that of the natural population (p > 0.05). There was no significant difference in the embryonic malformation rate between the two study groups compared to the normal pregnancy group (p > 0.05). Conclusion: Pregnant pituitary prolactinoma patients should not stop bromocriptine treatment, but should instead continue with the same dose for four months. For patients with macroadenoma, bromocriptine should be taken during the entire pregnancy. Blood prolactin, progesterone, human chorionic gonadotropin (hCG), and visual dysfunction should be monitored every two weeks during treatment. Patients should be treated with progesterone and hCG if the blood levels become too low. If regular monitoring shows that prolactin has increased too fast and/or visual dysfunction worsened, the dose of bromocriptine should be increased. The authors have found that bromocriptine treatment during pregnancy significantly reduces the embryo stop rate without increasing the embryo deformity rate; therefore, bromocriptine treatment is safe and necessary during pregnancy of pituitary prolactinoma patients.
Key words:  Pituitary adenoma      Prolactin      Pregnancy      Bromocriptine     
Published:  10 April 2017     
*Corresponding Author(s):  W. LIAN     E-mail:  weilian996@163.com

Cite this article: 

W. Lian, N. Liu, R.Z. Wang, B. Xing, Y. Yao. Analysis of bromocriptine treatment in pregnant pituitary prolactinoma patients. Clinical and Experimental Obstetrics & Gynecology, 2017, 44(2): 203-207.

URL: 

https://ceog.imrpress.com/EN/10.12891/ceog3262.2017     OR     https://ceog.imrpress.com/EN/Y2017/V44/I2/203

[1] Amanda M. Wang, Alan J. Lee, Shannon M. Clark. The effects of overweight and obesity on pregnancy-related morbidity[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(5): 999-1009.
[2] Leen Van den Eeden, Greet Leysens,Dominique Mannaerts, Yves Jacquemyn. Air pollution: cardiovascular and other negative effects on pregnancy: a narrative review[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(5): 1010-1016.
[3] Xin Du, Qian Zou, Yu-Lan Liu. Transumbilical single-hole laparoscopic treatment of cesarean scar pregnancy by uterine artery pre-ligation: a report of 4 cases[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(5): 1044-1047.
[4] Marcelo Epsztein Kanczuk, Nicholas J Lightfoot, Alison Pighills, Antony Ji, Casey Steele, Daniel Bartlett. The time to perform spinal or general anaesthesia in COVID-19 positive parturients requiring emergency caesarean delivery: a prospective crossover simulation study[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(5): 1099-1106.
[5] Noor Hazim Abdulkareem, Elham Hazeim Abdulkareem. SARS-CoV-2 detection in pregnant and non-pregnant women[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(5): 1141-1145.
[6] Min Jung Kim, Hee-Sook Lim, Hae-Hyeog Lee, Tae-Hee Kim, Yongsoon Park. Dietary assessment, nutrition knowledge, and pregnancy outcome in high-risk pregnant Korean women[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(5): 1178-1185.
[7] Neha Sethi, Ann Gee Tan, Maherah Kamarudin, Sofiah Sulaiman. Successful delivery of a twin pregnancy with complete hydatidiform mole and coexistent live fetus: a case report and review of literature[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(5): 1232-1247.
[8] Luca Roncati, Greta Gianotti, Elisa Ambrogi, Giovanna Attolini. COVID-19 in pregnancy[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(4): 778-780.
[9] Silvia Amodeo, Giulia Bonavina, Anna Seidenari, Paolo Ivo Cavoretto, Antonio Farina. Real-world implementation and adaptation to local settings of first trimester preeclampsia screening in Italy: a systematic review[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(4): 812-819.
[10] Yu Deng, Zhan-Hui Ou, Min-Na Yin, Pei-Ling Liang, Zhi-Heng Chen, Abraham Morse, Ling Sun. Age and anti-Műllerian hormone: prediction of cumulative pregnancy outcome in in vitro fertilization with diminished ovarian reserve[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(4): 835-841.
[11] Serdar Balci. The effect of ultraviolet index measurements on levels of vitamin D andinflammatory markers in pregnant women[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(4): 888-892.
[12] Anna M. Rubinshtein, Oleg V. Golyanovskiy. Obstetric outcomes in women of advanced maternal age after assisted reproduction[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(4): 893-900.
[13] Qian Hu, Mohammed Sharooq Paramboor, Tao Guo. Diagnosis and management of intramural ectopic pregnancy[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(4): 974-979.
[14] Ovadya Rosenbluh, Asnat Walfisch. Birth defects associated with obesity[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(3): 472-477.
[15] Sara Oday, Maysoon Sharief. The role of salivary progesterone and cervical length measurement in predicting risk of spontaneous preterm birth[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(3): 509-513.
No Suggested Reading articles found!